Palvella Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Palvella Therapeutics, Inc. (PVLA) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-17.43-24.54-33.28-45.74-37.20-25.47-26.75
Depreciation & Amortization0.001.902.772.462.131.040.57
Deferred Income Tax0.000.000.000.000.160.00-0.16
Stock Based Compensation0.830.600.430.000.000.000.00
Change in Working Capital-0.19-36.77-32.3831.51-15.66-32.1221.89
Change in Accounts Receivable-1.980.000.000.000.000.000.00
Change in Accounts Payable2.24-2.251.980.000.000.000.00
Change in Other Working Capital-0.45-29.3610.360.000.000.000.00
Other Operating Activities5.965.643.334.114.24-0.070.08
Net Cash from Operating Activities-10.84-53.82-59.93-7.66-45.90-52.47-1.07
Investing Activities
Capital Expenditures0.000.171.040.952.73-2.46-1.70
Sales/Maturities of Investments0.0012.17-20.200.0041.9412.30-7.18
Net Cash from Investing Activities0.0012.00-21.24-0.9539.219.84-8.88
Financing Activities
Debt Repayment78.430.000.000.000.000.000.00
Common Stock Issued0.0019.807.1257.279.8231.0047.21
Other Financing Activities8.665.000.000.000.000.000.00
Net Cash from Financing Activities87.0919.807.2159.1310.1232.1748.51
Summary
Effect of Forex Changes on Cash0.000.78-5.18-3.194.75-2.14-1.58
Net Change in Cash76.25-22.02-73.9547.338.18-10.4638.57
Cash at Beginning of Period7.3538.64117.7670.4462.2674.8737.88
Cash at End of Period83.6017.4038.6470.4470.4462.2674.87
Free Cash Flow-10.84-53.99-60.97-8.61-48.62-54.93-2.76
Supplemental Disclosures
Income Taxes Paid0.000.000.000.000.000.000.91